World Immunoprotein Diagnostic Testing Market - Opportunities and Forecasts, 2014 - 2022

  • ID: 3773144
  • Report
  • Region: Global
  • 199 pages
  • Allied Analytics LLP
1 of 4
Immunoprotein is an immunologically active protein, which provides immunity against pathogenic organisms or substances. These proteins form the integrated body system of tissues, organs, cells, or cell products that neutralize antigens. They enable the diagnosis of various diseases, such as cardiovascular, oncology, infectious diseases, and others, as they display an abnormal increase in their concentration when in a diseased state. Increase in incidence & prevalence of chronic diseases, rise in geriatric population, and growth in demand for early diagnostic services drive the market growth. However, complex regulatory framework for immunoprotein diagnostic testing limits the growth. The global immunoprotein diagnostic testing market is accounted for $16,485 million in 2016, and is estimated to reach $27,290 million by 2022, growing at a CAGR of 7.4% during the analysis period (2017-2023).

The market is segmented on the basis of type, application, technology, and geography. By type, the market is categorized into C-reactive protein diagnostic test, complement system protein diagnostic test, prealbumin diagnostic test, haptoglobin diagnostic test, immunoglobulin diagnostic test, free light chain diagnostic test, and others. Applications covered in the study include autoimmune disease testing, infectious disease testing, allergy testing, endocrine testing, oncology testing, toxicology testing, and others. Based on technology, it is classified into radioimmunoassay, immunoturbidity assay, chemiluminescence assay, immunoprotein electrophoresis, enzyme-based immunoassay, immunofluorescence assay, and others. Geographically, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

KEY MARKET BENEFITS

The study provides an in-depth analysis of the global immunoprotein diagnostic testing market with current trends and future estimations to elucidate the investment pockets.
Comprehensive analysis of factors that drive and restrict the growth of the market is provided.
The report provides a quantitative analysis for the period of 2016-2023, which enables stakeholders to capitalize on prevailing market opportunities.
Extensive analysis of different segments facilitates to understand the various products of the market.
Key players are profiled and their strategies are analyzed thoroughly, which predict the competitive outlook of the market.

KEY MARKET SEGMENT:

By Technology

Radioimmunoassay
Immunoturbidity Assay
Chemiluminescence Assay
Immunoprotein Electrophoresis
Enzyme-Based Immunoassay
Immunofluorescence Assay
Others

By Type

C-reactive Protein Diagnostic Test
Complement System Protein Diagnostic Test
Prealbumin Diagnostic Test
Haptoglobin Diagnostic Test
Immunoglobulin Diagnostic Test
Free Light Chain Diagnostic Test
Others

By Application

Autoimmune Testing
Infectious Disease Testing
Allergy Testing
Endocrine Testing
Oncology Testing
Toxicology Testing
Others

By Geography

North America
U.S.
Canada
Mexico
Europe
Germany
UK
France
Spain
Italy
Others
Asia Pacific
Japan
China
India
Others
LAMEA
Latin America
Middle East
Africa

List of players profiled in the report

Abbott Laboratories
Abcam PLC
Bio-Rad Laboratories
Danaher Corporation
Diasorin
Enzo Life Sciences
Ortho Clinical Diagnostics
Roche Diagnostics
Siemens Healthcare
Thermo Fisher Scientific

List of other players (These companies are not profiled in the report and same can be done on demand)

Affymetrix
Alere
bioMérieux
ORGENTEC Diagnostika
Sekisui Diagnostics
IBL International
ImmunoDX
Quidel Corporation
Trinity Biotech
READ MORE
Note: Product cover images may vary from those shown
2 of 4
CHAPTER 1 INTRODUCTION
1.1. REPORT DESCRIPTION
1.2. KEY BENEFITS
1.3. KEY MARKET SEGMENT
1.4. RESEARCH METHODOLOGY
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models

CHAPTER 2 EXECUTIVE SUMMARY
2.1. KEY FINDINGS OF THE STUDY
2.2. CXO PERSPECTIVE

CHAPTER 3 MARKET OVERVIEW
3.1. MARKET DEFINITION AND SCOPE
3.2. KEY FINDINGS
3.2.1. Top investment pockets
3.2.2. Top winning strategies
3.3. PORTERS FIVE FORCES ANALYSIS
3.3.1. Bargaining power of buyers
3.3.2. Bargaining power of suppliers
3.3.3. Threat of substitutes
3.3.4. Threat of new entrants
3.3.5. Competitive rivalry
3.4. TOP PLAYERS POSITIONING, 2016
3.5. MARKET DYNAMICS
3.5.1. Drivers
3.5.1.1. Increase in geriatric population and surge in incidence and prevalence of chronic diseases
3.5.1.2. Increase in government expenditure in the healthcare sector
3.5.2. Restraint
3.5.2.1. Complex regulatory framework
3.5.3. Opportunity
3.5.3.1. Lucrative opportunities from emerging economies

CHAPTER 4 IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET, BY TECHNOLOGY
4.1. OVERVIEW
4.1.1. Market size and forecast
4.2. RADIOIMMUNOASSAY
4.2.1. Key market trends
4.2.2. Key growth factors and opportunities
4.2.3. Market size and forecast
4.3. IMMUNOTURBIDITY ASSAY
4.3.1. Key market trends
4.3.2. Key growth factors and opportunities
4.3.3. Market size and forecast
4.4. CHEMILUMINESCENCE ASSAY
4.4.1. Key market trends
4.4.2. Key growth factors and opportunities
4.4.3. Market size and forecast
4.5. IMMUNOPROTEIN ELECTROPHORESIS
4.5.1. Key market trends
4.5.2. Key growth factors and opportunities
4.5.3. Market size and forecast
4.6. ENZYME-BASED IMMUNOASSAY
4.6.1. Key market trends
4.6.2. Key growth factors and opportunities
4.6.3. Market size and forecast
4.7. IMMUNOFLUORESCENCE ASSAY
4.7.1. Key market trends
4.7.2. Key growth factors and opportunities
4.7.3. Market size and forecast
4.8. OTHER TECHNOLOGY
4.8.1. Key market trends
4.8.2. Key growth factors and opportunities
4.8.3. Market size and forecast

CHAPTER 5 IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET, BY TYPE
5.1. OVERVIEW
5.1.1. Market size and forecast
5.2. C-REACTIVE PROTEIN DIAGNOSTIC TEST
5.2.1. Market size and forecast
5.3. COMPLEMENT SYSTEM PROTEIN DIAGNOSTIC TEST
5.3.1. Market size and forecast
5.4. PREALBUMIN DIAGNOSTIC TEST
5.4.1. Market size and forecast
5.5. HAPTOGLOBIN DIAGNOSTIC TEST
5.5.1. Market size and forecast
5.6. IMMUNOGLOBULIN DIAGNOSTIC TEST
5.6.1. Market size and forecast
5.7. FREE LIGHT CHAIN DIAGNOSTIC TEST
5.7.1. Market size and forecast
5.8. OTHER IMMUNOPROTEIN DIAGNOSTIC TEST
5.8.1. Market size and forecast

CHAPTER 6 IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET, BY APPLICATION
6.1. OVERVIEW
6.1.1. Market size and forecast
6.2. AUTOIMMUNE TESTING
6.2.1. Market size and forecast
6.3. INFECTIOUS DISEASE TESTING
6.3.1. Market size and forecast
6.4. ALLERGY TESTING
6.4.1. Market size and forecast
6.5. ENDOCRINE DISEASE TESTING
6.5.1. Market size and forecast
6.6. ONCOLOGY TESTING
6.6.1. Market size and forecast
6.7. TOXICOLOGY TESTING
6.7.1. Market size and forecast
6.8. OTHERS
6.8.1. Market size and forecast

CHAPTER 7 IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET, BY GEOGRAPHY
7.1. OVERVIEW
7.1.1. Market size and forecast
7.2. NORTH AMERICA
7.2.1. Key market trends
7.2.2. Key growth factors and opportunities
7.2.3. Market size and forecast
7.2.4. U.S. market size and forecast
7.2.5. Canada market size and forecast
7.2.6. Mexico market size and forecast
7.3. EUROPE
7.3.1. Key market trends
7.3.2. Key growth factors and opportunities
7.3.3. Market size and forecast
7.3.4. Germany market size and forecast
7.3.5. France market size and forecast
7.3.6. UK market size and forecast
7.3.7. Italy market size and forecast
7.3.8. Spain market size and forecast
7.3.9. Rest of Europe market size and forecast
7.4. ASIA-PACIFIC
7.4.1. Key market trends
7.4.2. Key growth factors and opportunities
7.4.3. Market size and forecast
7.4.4. Japan market size and forecast
7.4.5. China market size and forecast
7.4.6. India market size and forecast
7.4.7. Rest of Asia-Pacific market size and forecast
7.5. LAMEA
7.5.1. Key market trends
7.5.2. Key growth factors and opportunities
7.5.3. Market size and forecast
7.5.4. Latin America market size and forecast
7.5.5. Middle East market size and forecast
7.5.6. Africa market size and forecast

CHAPTER 8 COMPANY PROFILES
8.1. ABBOTT LABORATORIES
8.1.1. Company overview
8.1.2. Company snapshot
8.1.3. Operating business segments
8.1.4. Product portfolio
8.1.5. Business performance
8.1.6. Key strategic moves and developments
8.2. ABCAM PLC
8.2.1. Company overview
8.2.2. Company snapshot
8.2.3. Operating business segments
8.2.4. Product portfolio
8.2.5. Business performance
8.2.6. Key strategic moves and developments
8.3. BIO-RAD LABORATORIES, INC.
8.3.1. Company overview
8.3.2. Company snapshot
8.3.3. Operating business segments
8.3.4. Product portfolio
8.3.5. Business performance
8.3.6. Key strategic moves and developments
8.4. DANAHER CORPORATION
8.4.1. Company overview
8.4.2. Company snapshot
8.4.3. Operating business segment
8.4.4. Product portfolio
8.4.5. Business performance
8.5. DIASORIN S.P.A
8.5.1. Company overview
8.5.2. Company snapshot
8.5.3. Operating business segments
8.5.4. Product portfolio
8.5.5. Business performance
8.5.6. Key strategic moves and developments
8.6. ENZO BIOCHEM, INC.
8.6.1. Company overview
8.6.2. Company snapshot
8.6.3. Operating business segments
8.6.4. Operating business segments
8.6.5. Business performance
8.6.6. Key strategic moves and developments
8.7. F. HOFFMANN-LA ROCHE AG (ROCHE DIAGNOSTICS)
8.7.1. Company overview
8.7.2. Company snapshot
8.7.3. Operating business segments
8.7.4. Product portfolio
8.7.5. Business performance
8.7.6. Key strategic moves and developments
8.8. ORTHO CLINICAL DIAGNOSTICS
8.8.1. Company overview
8.8.2. Company snapshot
8.8.3. Operating business segments
8.8.4. Product portfolio
8.8.5. Key strategic moves and developments
8.9. SIEMENS AKTIENGESELLSCHAFT
8.9.1. Company overview
8.9.2. Company snapshot
8.9.3. Operating segments
8.9.4. Product portfolio
8.9.5. Business performance
8.10. THERMO FISHER SCIENTIFIC INC
8.10.1. Company overview
8.10.2. Company snapshot
8.10.3. Operating business segments
8.10.4. Product portfolio
8.10.5. Business performance

List of Tables
Table 1. Global Incidence Rates Of Diseases
Table 2. Global Immunoprotein Diagnostic Testing Market, By Technology, 2016-2023 ($Million)
Table 3. Radioimmunoassay Based Immunoprotein Diagnostic Testing Market, By Geography, 2016-2023 ($Million)
Table 4. Immunoturbidity Assay Based Immunoprotein Diagnostic Testing Market, By Geography, 2016-2023 ($Million)
Table 5. Chemiluminescence Assay Based Immunoprotein Diagnostic Testing Market, By Geography, 2016-2023 ($Million)
Table 6. Immunoprotein Electrophoresis Based Immunoprotein Diagnostic Testing Market, By Geography, 2016-2023 ($Million)
Table 7. Enzyme Immunoassay Based Immunoprotein Diagnostic Testing Market, By Geography, 2016-2023 ($Million)
Table 8. Immunofluorescence Assay Based Immunoprotein Diagnostic Testing Market, By Geography, 2016-2023 ($Million)
Table 9. Immunoprotein Diagnostic Testing Market For Other Technology, By Geography, 2016-2023 ($Million)
Table 10. Global Immunoprotein Diagnostic Testing Market, By Type, 2016-2023 ($Million)
Table 11. C-Reactive Protein Diagnostic Tests Market, By Geography, 2016-2023 ($Million)
Table 12. Complement System Protein Diagnostic Tests Market, By Geography, 2016-2023 ($Million)
Table 13. Prealbumin Diagnostic Tests Market, By Geography, 2016-2023 ($Million)
Table 14. Haptoglobin Diagnostic Tests Market, By Geography, 2016-2023 ($Million)
Table 15. Immunoglobulin Diagnostic Tests Market, By Geography, 2016-2023 ($Million)
Table 16. Free Light Chain Diagnostic Tests Market, By Geography, 2016-2023 ($Million)
Table 17. Other Immunoprotein Diagnostic Testing Market, By Geography, 2016-2023 ($Million)
Table 18. Immunoprotein Diagnostic Testing Market, By Application, 2016-2023 ($Million)
Table 19. Immunoprotein Diagnostic Testing Market For Autoimmune Diseases, By Geography, 2016-2023 ($Million)
Table 20. Infectious Diseases Caused By Specific Hosts
Table 21. Immunoprotein Diagnostic Testing Market For Infectious Diseases, By Geography, 2016-2023 ($Million)
Table 22. Types Of Allergy And Their Prevalence
Table 23. Immunoprotein Diagnostic Testing Market For Allergy, By Geography, 2016-2023 ($Million)
Table 24. Immunoprotein Diagnostic Testing Market For Endocrine Diseases, By Geography, 2016-2023 ($Million)
Table 25. Immunoprotein Diagnostic Testing Market For Oncology, By Geography, 2016-2023 ($Million)
Table 26. Immunoprotein Diagnostic Testing Market For Toxicology Testing, By Geography, 2016-2023 ($Million)
Table 27. Immunoprotein Diagnostic Testing Market For Other Applications, By Geography, 2016-2023 ($Million)
Table 28. Immunoprotein Diagnostic Testing Market, By Geography, 2016-2023 ($Million)
Table 29. North America Immunoprotein Diagnostic Testing Market, By Country, 2016-2023 ($Million)
Table 30. North America Immunoprotein Diagnostic Testing Market, By Technology, 2016-2023 ($Million)
Table 31. North America Immunoprotein Diagnostic Testing Market, By Type, 2016-2023 ($Million)
Table 32. North America Immunoprotein Diagnostic Testing Market, By Application, 2016-2023 ($Million)
Table 33. Europe Immunoprotein Diagnostic Testing Market, By Country, 2016-2023 ($Million)
Table 34. Europe Immunoprotein Diagnostic Testing Market, By Technology, 2016-2023 ($Million)
Table 35. Europe Immunoprotein Diagnostic Testing Market, By Type, 2016-2023 ($Million)
Table 36. Europe Immunoprotein Diagnostic Testing Market, By Application, 2016-2023 ($Million)
Table 37. Asia-Pacific Immunoprotein Diagnostic Testing Market, By Country, 2016-2023 ($Million)
Table 38. Asia-Pacific Immunoprotein Diagnostic Testing Market, By Technology, 2016-2023 ($Million)
Table 39. Asia-Pacific Immunoprotein Diagnostic Testing Market, By Type, 2016-2023 ($Million)
Table 40. Asia-Pacific Immunoprotein Diagnostic Testing Market, By Application, 2016-2023 ($Million)
Table 41. Lamea Immunoprotein Diagnostic Testing Market, By Region, 2016-2023 ($Million)
Table 42. Lamea Immunoprotein Diagnostic Testing Market, By Technology, 2016-2023 ($Million)
Table 43. Lamea Immunoprotein Diagnostic Testing Market, By Type, 2016-2023 ($Million)
Table 44. Lamea Immunoprotein Diagnostic Testing Market, By Application, 2016-2023 ($Million)
Table 45. Abbott: Company Snapshot
Table 46. Abbott: Operating Segments
Table 47. Abbott: Product Portfolio
Table 48. Abcam: Company Snapshot
Table 49. Abcam: Operating Segments
Table 50. Abcam: Operating Segments
Table 51. Bio-Rad: Company Snapshot
Table 52. Bio-Rad: Operating Segments
Table 53. Bio-Rad: Product Portfolio
Table 54. Danaher: Company Snapshot
Table 55. Danaher: Operating Segments
Table 56. Danaher: Product Portfolio
Table 57. Diosorin: Company Snapshot
Table 58. Diosorin: Operating Segments
Table 59. Diosorin: Product Portfolio
Table 60. Enzo: Snapshot
Table 61. Enzo: Operating Segments
Table 62. Enzo: Product Portfolio
Table 63. Roche: Company Snapshot
Table 64. Roche: Operating Segment
Table 65. Roche: Product Portfolio
Table 66. Ortho Clinical Diagnostics: Company Snapshot
Table 67. Ortho Clinical Diagnostics: Operating Segments
Table 68. Ortho Clinical Diagnostics: Product Portfolio
Table 69. Siemens: Company Snapshot
Table 70. Seimens: Operating Segments
Table 71. Siemens: Product Portfolio
Table 72. Thermo Fisher: Company Snapshot
Table 73. Thermo Fisher: Operating Segments
Table 74. Thermo Fisher: Product Portfolio

List of Figures
Figure 1. Global Immunoprotein Diagnostic Testing Market, 2016-2023
Figure 2. Immunoprotein Diagnostic Testing Market, By Geography, 2016-2023
Figure 3. Market Segmentation
Figure 4. Top Investment Pockets
Figure 5. Top Winning Strategies, 2014-2016 (%)
Figure 6. Top Winning Strategies: Nature And Type
Figure 7. Top Player Positioning: Immunoprotein Diagnostic Testing Market, 2016
Figure 8. Incidence Rate Of Chronic Diseases, 1995-2030
Figure 9. U.S. Healthcare Expenditure Per Person (USd)
Figure 10. Rising Gdp Of Many Countries ($Trillion)
Figure 11. Number Of Diagnosed Cancer Cases Worldwide
Figure 12. Global Common Cancer Statistics, 2012-2030
Figure 13. Specific Illicit Drug Dependence Or Abuse In The U.S., 2013
Figure 14. U.S. Immunoprotein Diagnostic Testing Market, 2016-2023 ($Million)
Figure 15. Canada Immunoprotein Diagnostic Testing Market, 2016-2023 ($Million)
Figure 16. Mexico Immunoprotein Diagnostic Testing Market, 2016-2023 ($Million)
Figure 17. Germany Immunoprotein Diagnostic Testing Market, 2016-2023 ($Million)
Figure 18. France Immunoprotein Diagnostic Testing Market, 2016-2023 ($Million)
Figure 19. UK Immunoprotein Diagnostic Testing Market, 2016-2023 ($Million)
Figure 20. Italy Immunoprotein Diagnostic Testing Market, 2016-2023 ($Million)
Figure 21. Spain Immunoprotein Diagnostic Testing Market, 2016-2023 ($Million)
Figure 22. Rest Of Europe Immunoprotein Diagnostic Testing Market, 2016-2023 ($Million)
Figure 23. Japan Immunoprotein Diagnostic Testing Market, 2016-2023 ($Million)
Figure 24. China Immunoprotein Diagnostic Testing Market, 2016-2023 ($Million)
Figure 25. India Immunoprotein Diagnostic Testing Market, 2016-2023 ($Million)
Figure 26. Rest Of Asia-Pacific Immunoprotein Diagnostic Testing Market, 2016-2023 ($Million)
Figure 27. Latin America Immunoprotein Diagnostic Testing Market, 2016-2023 ($Million)
Figure 28. Middle East Immunoprotein Diagnostic Testing Market, 2016-2023 ($Million)
Figure 29. Africa Immunoprotein Diagnostic Testing Market, 2016-2023 ($Million)
Figure 30. Abbott: Revenue, 2014-2016 ($Million)
Figure 31. Abbott: Revenue By Segment, 2016 (%)
Figure 32. Abbott: Revenue By Geography, 2016 (%)
Figure 33. Abcam: Revenue, 2014-2016 ($Million)
Figure 34. Abcam: Revenue By Geography, 2016 (%)
Figure 35. Bio-Rad: Revenue, 2014-2016 ($Million)
Figure 36. Bio-Rad: Revenue Share By Segment, 2016 (%)
Figure 37. Bio-Rad: Revenue Share By Geography, 2016 (%)
Figure 38. Danaher: Revenue, 2014-2016 ($Million)
Figure 39. Danaher: Revenue Share By Segment, 2016 (%)
Figure 40. Danaher: Revenue Share By Geography, 2016 (%)
Figure 41. Diosorin: Revenue, 2013-2015 ($Million)
Figure 42. Diosorin: Revenue By Geography, 2015 (%)
Figure 43. Enzo: Revenue, 2014-2016 ($Million)
Figure 44. Enzo: Revenue Share By Segment, 2016 (%)
Figure 45. Enzo: Revenue Share By Geography, 2016 (%)
Figure 46. Roche: Revenue, 2014-2016 ($Million)
Figure 47. Roche: Revenue By Segment, 2016 (%)
Figure 48. Roche: Revenue By Geography, 2016 (%)
Figure 49. Siemens: Revenue, 2014-2016 ($Million)
Figure 50. Siemens: Revenue Share By Segment, 2016 (%)
Figure 51. Siemens: Revenue Share By Geography, 2016 (%)
Figure 52. Thermo Fisher: Revenue, 2014-2016 ($Million)
Figure 53. Thermo Fisher: Revenue Share By Segment, 2016 (%)
Figure 54. Thermo Fisher: Revenue Share By Geography, 2016 (%)
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
Immunoprotein Diagnostic Testing Market report, forecasts that the global market was valued at $16,485 million in 2016 and is expected to garner $27,290 million by 2022, registering a CAGR of 7.4% during the forecast period 2017 - 2023. The enzyme-based immunoassay segment held one-third share of the total market in 2016.

Immunoprotein is a protein that possesses immunological activity, which provides immunity against pathogenic organisms or substances. High prevalence of diseases such as cancer, cardiovascular diseases, allergies, urological disorders, and orthopedic diseases majorly drives the market. However, stringent regulatory framework with regards to immunoprotein diagnostic tests is projected to restrain the market growth during the forecast period.

The global immunoprotein diagnostic testing market is segmented based on type, application, technology, and geography. Based on technology, the market is classified into radioimmunoassay, immunoturbidity assay, chemiluminescence assay, immunoprotein electrophoresis, enzyme-based immunoassay, and immunofluorescence assay. The enzyme-based immunoassay segment held the largest share of one-third in 2016, owing to wide application of enzyme-based immunoassay.

The immunoglobulin diagnostic test segment held the largest share in 2016, owing to the high adoption of immunoglobulin diagnostic test for the detection of excess or deficiency of immunoglobulins that provides information about the functioning of the immune system.

The infectious disease segment dominated the market in 2016, owing to the high incidence of infectious diseases and hence high usage of immunoprotein diagnostic testing for the detection of infectious diseases.

North America accounted for around two-fifths of the share in 2016, and is expected to dominate the market throughout the forecast period. This is attributed to increase in incidence of diseases due to rise in geriatric population, well-established healthcare systems, and increase in awareness among the population toward timely diagnosis of diseases. In addition, higher adoption rate for technologically advanced devices is anticipated to provide new growth opportunities for the key players in the market. However, Asia-Pacific is projected to grow at the highest during the analysis period, owing to rise in healthcare expenditure, increase in per capita income, growth in demand for healthcare services from large pool of patient population, and improvement in healthcare infrastructure.

Key Findings of Immunoprotein Diagnostic Testing Market

By type, the immunoglobulin diagnostic tests segment dominated the market in 2016, and is projected to grow at the highest CAGR.
By application, the infectious disease testing segment accounted for the highest share of two-sevenths in 2016.
The U.S. was the major shareholder in the North America immunoprotein diagnostic testing market, accounting for seven-eighths share in 2016.
Asia-Pacific is expected to show the highest growth rate during the analysis period.
China is expected to grow at the highest CAGR in the Asia-Pacific immunoprotein diagnostic testing market.

The major players profiled in the global cancer immunotherapy market are Abbott Laboratories, Abcam PLC, Bio-Rad Laboratories, Danaher Corporation, Diasorin, Enzo Life Sciences, Ortho Clinical Diagnostics, Roche Diagnostics, Siemens Healthcare, and Thermo Fisher Scientific.
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll